Korea Approves DPP-4 Inhibitor From LG Life Sciences; China And India Next?
This article was originally published in PharmAsia News
Executive Summary
After winning Korea approval, LG is looking to launch its diabetes product in China and India in 2014, but it will have to compete with existing MNC products to gain market share.